Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN R VANDERZYL

Allopathic & Osteopathic Physicians Family Medicine

NPI
1396848990
CMS profile
289946
Location
SUGAR LAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,850.73

152 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,842.28 151
Education $8.45 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN R VANDERZYL

NPI 1396848990 · CMS profile ID 289946

Allopathic & Osteopathic Physicians / Family Medicine

SUGAR LAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396848990?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN R VANDERZYL, NPI 1396848990, CMS profile ID 289946. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396848990?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JOHN R VANDERZYL, NPI 1396848990, CMS profile ID 289946. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396848990?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JOHN R VANDERZYL, NPI 1396848990, CMS profile ID 289946, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1396848990?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

152 matching records · $2,850.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 152 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 152.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Abbott Laboratories $15.0504/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018661587 CMS
Abbott Laboratories $3.2904/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018667245 CMS
Bayer Healthcare Pharmaceuticals Inc. $18.6304/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000122037 CMS
AbbVie Inc. $6.3104/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999388017 CMS
Novo Nordisk Inc $9.0504/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001487367 CMS
Amarin Pharma Inc. $16.5704/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000845915 CMS
AbbVie Inc. $11.2703/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999388011 CMS
Bayer Healthcare Pharmaceuticals Inc. $121.8603/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000202061 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.6703/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996977689 CMS
AbbVie Inc. $2.4603/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999388005 CMS
Abbott Laboratories $1.6603/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018657055 CMS
Abbott Laboratories $0.8003/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018665033 CMS
GlaxoSmithKline, LLC. $17.3203/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002194881 CMS
Abbott Laboratories $13.3703/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018637709 CMS
Amgen Inc. $6.3103/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019971295 CMS
Amgen Inc. $79.2503/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019971303 CMS
Abbott Laboratories $2.6803/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018636721 CMS
Abbott Laboratories $14.0603/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018636767 CMS
Bausch Health US, LLC $15.3103/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046944179 CMS
AbbVie Inc. $19.7903/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999387999 CMS
Abbott Laboratories $1.6602/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018654683 CMS
E.R. Squibb & Sons, L.L.C. $13.5502/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015980801 CMS
PFIZER INC. $7.6802/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050537865 CMS
Abbott Laboratories $12.4902/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018653729 CMS
Abbott Laboratories $2.8302/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018654181 CMS
AbbVie Inc. $22.6702/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999387993 CMS
Bayer Healthcare Pharmaceuticals Inc. $19.7302/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000135553 CMS
Lilly USA, LLC $12.8902/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031589861 CMS
Amgen Inc. $19.1602/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020604811 CMS
Abbott Laboratories $12.6402/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018650965 CMS
Abbott Laboratories $2.4902/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018651139 CMS
PFIZER INC. $16.2802/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049485981 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.5002/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057087429 CMS
Novo Nordisk Inc $7.7302/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001487343 CMS
Novo Nordisk Inc $14.8702/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001487397 CMS
IDORSIA PHARMACEUTICALS US INC $12.7402/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034409103 CMS
Novo Nordisk Inc $13.5402/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001487377 CMS
Abbott Laboratories $13.0002/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018648289 CMS
Novo Nordisk Inc $6.9602/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001487331 CMS
SANOFI PASTEUR INC. $22.2502/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043913957 CMS
GlaxoSmithKline, LLC. $28.3001/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002194847 CMS
Amarin Pharma Inc. $14.4001/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000897399 CMS
Abbott Laboratories $2.6801/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018645545 CMS
Abbott Laboratories $10.4201/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018645749 CMS
Amgen Inc. $5.5601/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019971293 CMS
Novo Nordisk Inc $0.8301/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001487237 CMS
Novo Nordisk Inc $14.5701/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001487387 CMS
Lilly USA, LLC $11.9401/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031604423 CMS
Abbott Laboratories $14.4601/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018642349 CMS
Lilly USA, LLC $25.5401/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031681249 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,420.75 116
PY2020 $1,987.39 128
PY2021 $2,911.31 143
PY2022 $2,398.66 111
PY2023 $2,850.73 152
PY2024 $3,189.08 133
PY2025 $3,122.49 114

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,685,576.87 26
PY2024 Principal investigator $658,718.88 149
PY2023 Principal investigator $923,756.34 1,050
PY2022 Principal investigator $411,200.39 520
PY2021 Principal investigator $26,625.90 5
PY2020 Principal investigator $39,730.10 6
PY2019 Principal investigator $140.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $19,003.80 12/10/2025 Non-covered Recipient Entity
Clinical Research Of South Nevada - Clinedge - Ppds
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215506435
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,377.40 12/10/2025 Non-covered Recipient Entity
Clinical Research Of South Nevada - Clinedge - Ppds
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215506440
Principal investigator 1 Amgen Inc. $621.00 10/28/2025 Non-covered Recipient Entity
SUGAR LAKES FAMILY PRACTICE, P.A.
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight No dispute reported 06/30/2026 1246648858
Principal investigator 1 Amgen Inc. $1,444.13 10/08/2025 Non-covered Recipient Entity
SUGAR LAKES FAMILY PRACTICE, P.A.
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246648862
Principal investigator 1 Novartis Pharmaceuticals Corporation $59,070.29 10/07/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190310080
Principal investigator 1 Amgen Inc. $138,582.40 06/26/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246641135
Principal investigator 1 Novo Nordisk AS $79.20 06/25/2025 Non-covered Recipient Entity
SUGAR LAKES FAMILY PRACTICE
NN9536-4999 No dispute reported 06/30/2026 1213847561
Principal investigator 1 Amgen Inc. $25,533.28 06/10/2025 Non-covered Recipient Entity
SUGAR LAKES FAMILY PRACTICE
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246648870
Principal investigator 1 Novo Nordisk AS $5,850.00 05/23/2025 Non-covered Recipient Entity
SUGAR LAKES FAMILY PRACTICE
NN9536-7545 No dispute reported 06/30/2026 1213726840
Principal investigator 1 Novo Nordisk AS $5,850.00 05/23/2025 Non-covered Recipient Entity
SUGAR LAKES FAMILY PRACTICE
NN9536-4999 No dispute reported 06/30/2026 1213759039
Principal investigator 1 Novo Nordisk AS $4,999.95 05/23/2025 Non-covered Recipient Entity
SUGAR LAKES FAMILY PRACTICE
NN9536-4999 No dispute reported 06/30/2026 1213768316
Principal investigator 1 Novo Nordisk AS $5,000.13 05/23/2025 Non-covered Recipient Entity
SUGAR LAKES FAMILY PRACTICE
NN9536-7545 No dispute reported 06/30/2026 1213840544
Principal investigator 1 PFIZER INC. $13,950.00 05/07/2025 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228772615
Principal investigator 1 Amgen Inc. $1,218,777.90 04/24/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight No dispute reported 06/30/2026 1246641125
Principal investigator 1 GlaxoSmithKline, LLC. $1,908.40 04/16/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 1192169095
Principal investigator 1 Amgen Inc. $139,091.27 02/25/2025 Non-covered Recipient Entity
SUGAR LAKES FAMILY PRACTICE
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight No dispute reported 06/30/2026 1246648866
Principal investigator 1 Novo Nordisk AS $38.14 02/21/2025 Non-covered Recipient Entity
SUGAR LAKES FAMILY PRACTICE
NN9536-4999 No dispute reported 06/30/2026 1213719870
Principal investigator 1 PFIZER INC. $16,315.00 02/08/2025 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228750597
Principal investigator 1 Novo Nordisk AS $6.00 02/02/2025 Non-covered Recipient Entity
SUGAR LAKES FAMILY PRACTICE
NN9536-4999 No dispute reported 06/30/2026 1213715033
Principal investigator 1 Novo Nordisk AS $70.00 01/31/2025 Non-covered Recipient Entity
SUGAR LAKES FAMILY PRACTICE
NN9536-4999 No dispute reported 06/30/2026 1213716054
Principal investigator 1 Novo Nordisk AS $275.00 01/31/2025 Non-covered Recipient Entity
SUGAR LAKES FAMILY PRACTICE
NN9536-7545 No dispute reported 06/30/2026 1213751811
Principal investigator 1 Novo Nordisk AS $17,164.60 01/31/2025 Non-covered Recipient Entity
SUGAR LAKES FAMILY PRACTICE
NN9536-4999 No dispute reported 06/30/2026 1213753437
Principal investigator 1 Novo Nordisk AS $600.00 01/31/2025 Non-covered Recipient Entity
SUGAR LAKES FAMILY PRACTICE
NN9536-4999 No dispute reported 06/30/2026 1213755592
Principal investigator 1 Novo Nordisk AS $1,000.00 01/31/2025 Non-covered Recipient Entity
SUGAR LAKES FAMILY PRACTICE
NN9536-4999 No dispute reported 06/30/2026 1213771678
Principal investigator 1 Novo Nordisk AS $1,968.98 01/31/2025 Non-covered Recipient Entity
SUGAR LAKES FAMILY PRACTICE
NN9536-7545 No dispute reported 06/30/2026 1213813764
Principal investigator 1 PFIZER INC. $5,000.00 01/25/2025 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228799826